Premium
Combination antifungal therapy for Scedosporium species in cystic fibrosis
Author(s) -
Bentley Siân,
Davies Jane C.,
Carr Siobhán B.,
BalfourLynn Ian M.
Publication year - 2020
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/ppul.24789
Subject(s) - scedosporium apiospermum , posaconazole , medicine , terbinafine , cystic fibrosis , adverse effect , antifungal , lung function , surgery , mycosis , voriconazole , dermatology , lung , itraconazole
Abstract Objective To evaluate safety and efficacy of oral posaconazole and terbinafine for Lomentospora prolificans and Scedosporium apiospermum in children with cystic fibrosis. Methods Retrospective case review. Results There were five children (four girls), median age 15.0 years; three had S. apiospermum and two had L. prolificans . Treatment duration: median 5 months (range: 5‐18 m). In no patient was eradication achieved, with the follow‐up range being 6 months to 4 years. Effect on lung function was variable but encouraging. No adverse effects were reported, one child had transient elevation of liver enzymes. Conclusions While the combination therapy was well tolerated, it was unsuccessful at eradication.